|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Merz Pharmaceuticals GmbH |
|---|---|
| Information provided by: | Merz Pharmaceuticals GmbH |
| ClinicalTrials.gov Identifier: | NCT00430586 |
Purpose
NT 201 is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, NT 201 causes local weakening to full paralysis depending on the administered dose. Botulinum toxin type A is widely used for aesthetic treatment of facial lines. This study will determine the optimal dose of NT 201 in the treatment of glabellar frown lines.
| Condition | Intervention | Phase |
|---|---|---|
|
Glabellar Frown Lines |
Drug: Botulinum neurotoxin type A, free of complexing proteins |
Phase II |
| Study Type: | Interventional |
| Study Design: | Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations More Information
| Study ID Numbers: | MRZ 60201-0527/1 |
| Study First Received: | February 1, 2007 |
| Last Updated: | February 6, 2008 |
| ClinicalTrials.gov Identifier: | NCT00430586 |
| Health Authority: | United States: Food and Drug Administration |
|
Signs and Symptoms Botulinum Toxins Botulinum Toxin Type A |
